Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9313409 | 0.91 | MEN1 (0.67) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL19408173 | 0.91 | POLB (0.70) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL31590796 | 0.89 | HPGD (0.68) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL9180503 | 0.89 | HPGD (0.68) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL2092509 | 0.89 | HPGD (0.62) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL2092505 | 0.89 | HPGD (0.62) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL29678338 | 0.89 | HPGD (0.62) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL5858216 | 0.89 | HPGD (0.62) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL1391455 | 0.87 | CA1 (0.65) | POLBMEN1KMT2AHPGDUSP2 | |
| SCHEMBL31384762 | 0.87 | HPGD (0.60) | POLBMEN1KMT2AHPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124948-B1 | COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE VASCULAR DISORDERS AND CANCERS | NC BIT INC (KR) | 2017-07-26 | — | — | EP | disclosed |
| US-8106071-B2 | Compositions for treating hyperproliferative vascular disorders and cancers | BIOBUD CO., LTD. (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8106071-B2 | Compositions for treating hyperproliferative vascular disorders and cancers | BIOBUD CO., LTD. (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8106071-B2 | Compositions for treating hyperproliferative vascular disorders and cancers | BIOBUD CO., LTD. (KR) | 2012-01-31 | — | — | US | disclosed |
| US-20100120849-A1 | Compositions for Treating Hyperproliferative Vascular Disorders and Cancers | BIOBUD CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120849-A1 | Compositions for Treating Hyperproliferative Vascular Disorders and Cancers | BIOBUD CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120849-A1 | Compositions for Treating Hyperproliferative Vascular Disorders and Cancers | BIOBUD CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
| EP-2124948-A1 | COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE VASCULAR DISORDERS AND CANCERS | Biobud Co., Ltd. (KR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008102932-A1 | COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE VASCULAR DISORDERS AND CANCERS | BIOBUD CO., LTD. (KR) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008102932-A1 | COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE VASCULAR DISORDERS AND CANCERS | BIOBUD CO., LTD. (KR) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120849-A1 | Compositions for Treating Hyperproliferative Vascular Disorders and Cancers | MKI67, MYLK, PCNA | POLB 1762/4885MEN1 819/4885KMT2A 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.